BLRX BioLineRx Ltd.

0.87
+0  (2%)
Previous Close 0.85
Open 0.86
Price To book 1.38
Market Cap 53.69M
Shares 61,782,000
Volume 324,818
Short Ratio 0.37
Av. Daily Volume 646,892

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2a trial initiation announced January 17, 2017.
BL-8040 in combination with KEYTRUDA
Pancreatic cancer
Phase 2 initiated September 2016. Partial data due 2H 2017. Full data due 2H 2018.
BL-8040 in combination with KEYTRUDA - COMBAT trial
Pancreatic cancer
Development plans to be released by early 2017.
BL-7010
Gluten sensitivity
Phase 2b initiated August 2015. Interim analysis due in 2018, with top-line results expected in 2019.
BL-8040
Consolidation treatment for AML cancer patients
Phase 2 trial initiated March 2016. Partial data released March 20, 2017 with topline results by the end of 2017 with Phase 2/3 trial to be initiated 2H 2017.
BL-8040
Mobilization and collection of bone marrow stem cells
Phase 2 data released March 2016. Full set of data presented September 8, 2016
BL-8040
Acute myeloid leukemia (AML) cancer relapsed and refractory

Latest News

  1. BioLineRx Closes $28.75 Million Underwritten Public Offering of its American Depositary Shares
  2. Today's Research Reports on Biotech Stocks to Watch: Bioline RX and Cara Therapeutics
  3. BioLineRx Prices $25 Million Underwritten Public Offering
  4. BioLineRx Announces Underwritten Public Offering of its American Depositary Shares
  5. BioLineRx's AGI-134 to be Presented at AACR 2017
  6. BioLineRx Reports Year End 2016 Financial Results
  7. BioLineRx Announces Acquisition of Agalimmune Ltd. to Accelerate Expansion of Immuno-Oncology Pipeline
  8. BioLineRx Provides Update on Phase 2 Open-Label Study for BL-8040 as Novel Stem Cell Mobilization Treatment
  9. BioLineRx to Report Annual 2016 Results on March 23, 2017
  10. Two Biotech Catalysts To Watch Right Now: Bioline RX Ltd (BLRX) And AMAG Pharmaceuticals, Inc. (AMAG)
  11. BioLineRx to Present at 2017 BIO CEO & Investor Conference in New York on February 14
  12. BioLineRx (BLRX) Starts Cancer Study on BL-8040+Keytruda
  13. BioLineRx Announces Initiation of Immuno-Oncology Phase 2 Study to Investigate Combination of BL-8040 and KEYTRUDA® for Pancreatic Cancer
  14. BioLineRx to Present at Biotech Showcase 2017 Conference in San Francisco
  15. BioLineRx Presents Positive Phase 2a AML Study and Mechanism-of-Action Data for BL-8040 Oncology Platform at ASH 2016
  16. BioLineRx Reports Third Quarter 2016 Financial Results
  17. BioLineRx In-licenses Novel Anti-Inflammatory Treatment for Dry Eye Syndrome Under Strategic Collaboration with Major Global Pharmaceutical Company
  18. BioLineRx to Report Third Quarter Results on November 22, 2016
  19. Penny Ante: Ante Up For Bioline RX Ltd (BLRX) Stock
  20. BioLineRx Discloses Positive Correlative Data from Phase 2a AML Study and Mechanism-of-Action Data for BL-8040 Oncology Platform at ASH 2016